Champions Oncology Q4 revenue rises; margin improves driven by cost discipline
CSBR•Outlook
- Company did not provide specific guidance for future quarters or fiscal year
Result drivers
- Cost discipline - Co said lower outsourced research services expenses and compensation reduced cost of revenue, supporting higher margins
- In-house transition - Co said moving certain radiopharmaceutical activities in-house lowered costs and improved margins
- Strategic investments - Co continued to invest in commercial organization and data platform, increasing operating expenses
Key details and valuation
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q4 Revenue | $13.80 mln | ||
| Q4 Adjusted EPS | $0.01 | ||
| Q4 Loss Per Share | $0.05 |
The stock recently traded at 59 times the next 12-month earnings vs. a P/E of 56 three months ago.
Q4 revenue and profitability improve
- US oncology research provider's fiscal Q4 revenue rose 12% yr/yr to $13.8 mln
- Company posted positive adjusted EBITDA and adjusted EPS of $0.01 for the quarter
